Published in Cancer Weekly, July 15th, 2003
The phase I trial will be conducted at a single center and is expected to enroll approximately 70 healthy subjects in a dose-escalating study intended to explore the safety, pharmacokinetic, and pharmacodynamic merits of the compound following oral administration. The trial should be completed within a year. Concurrent with the phase I trial, Exelixis plans to explore the therapeutic utility of the compound in various animal models of disease outside of cancer, including renal and cardiovascular disease.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.